Selank
OtherAlso known as TP-7
Evidence tier
Multiple human trials
3 human trials · 1 observational
- Researched since
- 2001
- Publications
- 135
- Mean purity
- 99.6%
- Vendors listing
- 18
Modern Aminos shows the highest mean assayed purity for Selank at 99.9% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2001 — 25 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
135 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 20 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.28 pts purity across lots, mean label deviation 11.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
18 of 18 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
17 of 20 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Selank?
A synthetic heptapeptide based on the immune peptide tuftsin, studied in relation to anxiety and cognition. It was developed in Russia.
Studied in published research for anxiety, stress and cognition.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and in human clinical research conducted in Russia. PepIndex does not evaluate clinical significance and does not describe administration.
- Functional Connectomic Approach to Studying Selank and Semax Effects — Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections (2020)
Peer-reviewed article indexed in PubMed, published in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections (2020).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bulletin of experimental biology and medicine (2022)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2022).
- Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress — Bulletin of experimental biology and medicine (2019)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2019).
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress — Current reviews in clinical and experimental pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in Current reviews in clinical and experimental pharmacology (2021).
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats — Bulletin of experimental biology and medicine (2019)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2019).
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission — Frontiers in pharmacology (2016)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2016).
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells — Frontiers in pharmacology (2017)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2017).
Indexed studies4 human-evidence of 4
- [Optimization of the treatment of anxiety disorders with selank] — Human — controlled trial, 2015
To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clin…
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] — Human — controlled trial, 2014
Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a we…
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] — Human — controlled trial, 2008
Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients wit…
- Predictive factors of the presence of pulmonary embolism in patients with interstitial lung disease: Observational study — Human — observational, 2024
In patients with interstitial lung disease (ILD), the risk of pulmonary embolism (PE) is increased; however, distinguishing between PE and ILD exacerbation can be difficult. Therefore, this study investigated the usefulness of the Wells criteria and revised Geneva score and predictive factors for diagnosing PE in ILD patients with worsening respiratory symptoms. We retrospectively collected the data of 65 patients with ILD who underwent computed tomography pulmonary angiograp…
Evidence digest
What the research on Selank actually shows
The indexed literature on Selank includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Selank is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.897% | $1.59 (30%) | 3 | 99.6% | 5.4% | |
| CuroISO/IEC 17025 | 93.877% | — | 1 | 99.7% | 6.0% | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 1 | 99.8% | 40.0% | |
| PeptidePlugs | 89.790% | — | 3 | 99.8% | 14.8% | |
| Koi Peptides | 86.594% | $4.00 (67%) | 1 | 99.7% | 3.5% | |
| American PeptidesISO/IEC 17025 | 84.8100% | $6.50 (108%) | 3 | 99.8% | 19.6% | |
| Ascension Peptides | 81.486% | $5.00 (83%) | 1 | 99.3% | 22.9% | |
| NeuroLabs Research | 79.386% | — | 1 | 99.8% | 0.3% | |
| ZC Labs | 79.384% | — | 1 | 99.8% | 0.6% | |
| Northline LabsISO/IEC 17025 | 75.393% | $9.00 (150%) | 1 | 99.2% | 2.0% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.9% | 8.3% | |
| Simple Peptide | 7489% | — | 1 | 99.3% | 20.3% | |
| Improved Peptides | 73.789% | $4.90 (82%) | 0 | — | — | |
| Eternal Peptides | 7165% | $4.50 (75%) | 0 | — | — | |
| Good Science Bio | 70.575% | $6.50 (108%) | 0 | — | — | |
| BioLongevity Labs | 69.774% | $6.75 (113%) | 0 | — | — | |
| Evolve Peptides | 6667% | $6.00 (100%) | 0 | — | — | |
| Mile High Compounds | 62.494% | $6.50 (108%) | 2 | 99.0% | 1.5% |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Curo | SEL10ZO626 | BTLabs | 10 mg | 10.6 mg | 6.0% | 99.7% | Vendor-published | |
| Ascend Science | AS-SK5 | Kovera Labs and/or ILS Labs | 10 mg | 6 mg | 40.0% | 99.8% | Vendor-published | |
| Next Gen Peptides | SLK06 | ILS Laboratories | 10 mg | 10.56 mg | 5.6% | 99.6% | Vendor-published | |
| Next Gen Peptides | NSP-SSP-01 | ILS Laboratories | 60 mg | 63.59 mg | 6.0% | 99.6% | Vendor-published | |
| PeptidePlugs | 148-04-DK | Freedom Diagnostics Testing | 10 mg | 10.75 mg | 7.5% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-A3X3 | Analysis FreedomDiagnostics | 10 mg | 10.83 mg | 8.3% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2606260483 | Freedom Diagnostics Testing | 10 mg | 9.94 mg | 0.6% | 99.8% | Vendor-published | |
| American Peptides | SEMSEL5-0616 | Bioviridian Inc. | 10 mg | 5.39 mg | 46.1% | 99.9% | Vendor-published | |
| Koi Peptides | 612026SK | Freedom Diagnostics | 11 mg | 11.39 mg | 3.5% | 99.7% | Vendor-published | |
| American Peptides | SEL10-0528 | Bioviridian Inc. | 10 mg | 10.56 mg | 5.6% | 99.8% | Vendor-published | |
| NeuroLabs Research | NL02-SLK | Analysis FreedomDiagnostics | 10 mg | 10.03 mg | 0.3% | 99.8% | Vendor-published | |
| Simple Peptide | SELK10-052026-7 | Analysis FreedomDiagnostics | 10 mg | 12.03 mg | 20.3% | 99.3% | Vendor-published | |
| Northline Labs | NLL-9907743 | horizonanalytical.com | 10 mg | 9.8 mg | 2.0% | 99.2% | Vendor-published | |
| PeptidePlugs | 121-A-D | Freedom Diagnostics Testing | 10 mg | 9.46 mg | 5.4% | 99.9% | Vendor-published | |
| Next Gen Peptides | SL05 | ILS Laboratories | 10 mg | 10.47 mg | 4.7% | 99.7% | Vendor-published | |
| PeptidePlugs | 114-SM | Freedom Diagnostics Testing | 10 mg | 6.86 mg | 31.4% | 99.8% | Vendor-published | |
| American Peptides | SEL10-0318 | American Peptides | 10 mg | 10.72 mg | 7.2% | 99.6% | Vendor-published | |
| Ascension Peptides | 29-01260229 | MZ Biolabs | 10 mg | 12.29 mg | 22.9% | 99.3% | Vendor-published | |
| Mile High Compounds | SLK-010-MH-04 | Mile High Compounds | 10 mg | 9.9 mg | 1.0% | 99.0% | Vendor-published | |
| Mile High Compounds | SLK-010-MH-03 | Mile High Compounds | 10 mg | 9.8 mg | 2.0% | 99.0% | Vendor-published |